Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Alpha Tau Medical Ltd. The associated price target remains the same with $9.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Yi Chen has given his Buy rating due to a combination of factors related to Alpha Tau Medical Ltd’s promising clinical developments. The company recently initiated a U.S. pilot study for its Alpha DaRT technology in treating recurrent glioblastoma multiforme (GBM), a condition with a dire need for effective treatments due to its low average survival rate. The innovative delivery method of Alpha DaRT, which ensures extensive coverage of the tumor, is integrated with standard surgical navigation systems, indicating a significant advancement in treatment precision.
Additionally, Alpha Tau Medical is progressing with its U.S. pilot study for pancreatic cancer, which is expected to complete enrollment by the first quarter of 2026. This study, known as IMPACT, is exploring the combination of Alpha DaRT with chemotherapy for patients with challenging pancreatic cancer cases. Given the high incidence of inoperable pancreatic cancer, Alpha DaRT’s potential to meet this unmet need in oncology is noteworthy. These clinical advancements and the potential systemic response of Alpha DaRT support the Buy rating and the $9 price target set by Yi Chen.
In another report released today, Citi also maintained a Buy rating on the stock with a $7.00 price target.